AbbVie Inc. / Haisco Pharmaceutical Group Co., Ltd.

Moderate-to-severe acute pain (non-opioid)

80M US cases/yr · $17.1B US non-opioid pain treatment market (2024) · ~51,000,000 US annual surgical procedures (CDC)

Disease Overview

Acute pain from surgical procedures, trauma, and injury affects approximately 80 million Americans prescribed pain medication annually, per Vertex analyses cited at Journavx launch. The CDC reports approximately 51 million inpatient surgeries are performed annually in the US, with the Institute of Medicine estimating ~80% of surgical patients experience post-operative pain and 88% of those report moderate-to-severe discomfort. The acute pain market has historically been dominated by opioids (hydrocodone, oxycodone, morphine) and NSAIDs/acetaminophen, with NSAIDs alone representing ~55% of non-opioid pain revenue in 2024. The opioid crisis — responsible for ~80,000 US overdose deaths annually — has catalyzed payer, regulator, and physician demand for non-addictive alternatives. FDA approval of Vertex's Journavx (suzetrigine) in January 2025 as a first-in-class NaV1.8 inhibitor validated peripheral sodium-channel blockade as a commercially viable mechanism, with coverage already extending to two-thirds of US covered lives at WAC pricing of $15.50 per 50mg pill. This creates a defined beachhead for next-generation NaV1.8 inhibitors differentiated by potency, onset, IV formulations for inpatient settings, and oral convenience. Primary source: Vertex Pharmaceuticals Journavx FDA approval press release (January 2025).

Competitive Landscape

The NaV1.8 inhibitor landscape is narrowly concentrated and early-maturation, with Vertex holding first-mover status. (1) NaV1.8-selective inhibitors — Vertex's Journavx (suzetrigine) is the only approved agent, oral BID, indicated for moderate-to-severe acute pain; Vertex's follow-on VX-993 is in Phase 2 for acute and neuropathic pain. Haisco's HSK55718 (IV) and HSK51155 (oral) — now AbbVie-licensed ex-China — are the most advanced competitor assets, with IV formulation particularly differentiated for inpatient perioperative use where Journavx's oral route is limiting. (2) Broader non-opioid acute pain — Heron's Zynrelef (bupivacaine/meloxicam) and Pacira's Exparel (liposomal bupivacaine) are local/regional anesthetics; Trevena's Olinvyk is a biased mu-opioid. (3) Non-NaV1.8 novel mechanisms — NKTR-181 and CGRP antagonists have largely failed or withdrawn in acute pain. AbbVie's entry via Haisco provides a fast-follower NaV1.8 franchise with IV differentiation to compete with Vertex in hospital channel access.